1428 related articles for article (PubMed ID: 24283207)
21. Outcome of ablation of thyroid remnants with 100 mCi (3.7 GBq) iodine-131 in patients with thyroid cancer.
Rosário PW; Barroso AL; Rezende LL; Padrão EL; Fagundes TA; Reis JS; Purisch S
Ann Nucl Med; 2005 May; 19(3):247-50. PubMed ID: 15981681
[TBL] [Abstract][Full Text] [Related]
22. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
Scheffel RS; Zanella AB; Dora JM; Maia AL
Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of adjuvant therapy with 3.7 GBq radioactive iodine in intermediate-risk patients with 'higher risk features' and predictive value of postoperative nonstimulated thyroglobulin.
Rosario PW; Mourão GF; Calsolari MR
Nucl Med Commun; 2016 Nov; 37(11):1148-53. PubMed ID: 27341413
[TBL] [Abstract][Full Text] [Related]
24. Patients with Papillary Thyroid Carcinoma at Intermediate Risk of Recurrence According to American Thyroid Association Criteria Can Be Reclassified as Low Risk When the Postoperative Thyroglobulin Is Low.
Rosario PW; Furtado Mde S; Mourão GF; Calsolari MR
Thyroid; 2015 Nov; 25(11):1243-8. PubMed ID: 26359309
[TBL] [Abstract][Full Text] [Related]
25. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
26. Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up.
Ahtiainen V; Vaalavirta L; Tenhunen M; Joensuu H; Mäenpää H
Acta Oncol; 2020 Sep; 59(9):1064-1071. PubMed ID: 32603613
[No Abstract] [Full Text] [Related]
27. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
28. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
[TBL] [Abstract][Full Text] [Related]
29. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
[TBL] [Abstract][Full Text] [Related]
30. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?
Cailleux AF; Baudin E; Travagli JP; Ricard M; Schlumberger M
J Clin Endocrinol Metab; 2000 Jan; 85(1):175-8. PubMed ID: 10634383
[TBL] [Abstract][Full Text] [Related]
31. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
32. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial.
Schlumberger M; Leboulleux S; Catargi B; Deandreis D; Zerdoud S; Bardet S; Rusu D; Godbert Y; Buffet C; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Toubert ME; Kelly A; Benhamou E; Borget I
Lancet Diabetes Endocrinol; 2018 Aug; 6(8):618-626. PubMed ID: 29807824
[TBL] [Abstract][Full Text] [Related]
33. Day 3 thyroglobulin ≤ 1 ng/ml after recombinant human TSH just prior to radioactive iodine is predictive of low risk for persistent/recurrent disease in patients with papillary thyroid carcinoma.
Rosario PW; Siman TL; Calsolari MR
Endocrine; 2015 May; 49(1):170-4. PubMed ID: 25209895
[TBL] [Abstract][Full Text] [Related]
34. Is adjuvant therapy useful in patients with papillary carcinoma smaller than 2 cm?
Rosário PW; Borges MA; Valadão MM; Vasconcelos FP; Rezende LL; Padrão EL; Barroso AL; Purisch S
Thyroid; 2007 Dec; 17(12):1225-8. PubMed ID: 18001178
[TBL] [Abstract][Full Text] [Related]
35. Is postablation whole-body
Liu B; Chen Y; Jiang L; He Y; Huang R; Kuang A
Clin Endocrinol (Oxf); 2017 Jan; 86(1):134-140. PubMed ID: 27434740
[TBL] [Abstract][Full Text] [Related]
36. Is 131I ablation necessary for patients with low-risk papillary thyroid carcinoma and slightly elevated stimulated thyroglobulin after thyroidectomy?
Rosario PW; Mourão GF
Arch Endocrinol Metab; 2016 Feb; 60(1):5-8. PubMed ID: 26909477
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis.
Leboulleux S; Rubino C; Baudin E; Caillou B; Hartl DM; Bidart JM; Travagli JP; Schlumberger M
J Clin Endocrinol Metab; 2005 Oct; 90(10):5723-9. PubMed ID: 16030160
[TBL] [Abstract][Full Text] [Related]
38. Radioiodine remnant ablation in low-risk differentiated thyroid cancer.
Saengsuda Y
J Med Assoc Thai; 2013 May; 96(5):614-24. PubMed ID: 23745318
[TBL] [Abstract][Full Text] [Related]
39. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
[TBL] [Abstract][Full Text] [Related]
40. Management of low-risk patients with thyroid carcinoma and detectable thyroglobulin on T4 after thyroidectomy and ablation with iodine-131.
Rosário PW; Borges MA; Costa GB; Rezende LL; Padrão EL; Barroso AL; Purisch S
Arq Bras Endocrinol Metabol; 2007 Feb; 51(1):99-103. PubMed ID: 17435862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
